Memphis, TN — March 25, 2026 — SweetBio today announced the commercial launch of APIS®, its second bioengineered wound product, through a strategic distribution partnership with Resolve Medical. The partnership expands access to SweetBio's core technology, enabling clinicians to immediately treat a broader range of patients across the full wound healing spectrum.

APIS® is the first and only wound care product to combine UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite, a science-driven formulation engineered to support every stage of the healing cascade, from early-stage bacteria reduction and inflammation through proliferation and remodeling. APIS® is non-human, containing no placental, umbilical, or other human tissue — a distinction that simplifies the regulatory and billing landscape and opens a more straightforward path for clinicians looking for high-performance alternatives.

“APIS® represents a significant expansion for SweetBio and our technology,” said Kayla Rodriguez Graff, Co-Founder, Chief Executive Officer, SweetBio. “With VERIS™, we built a pathway to extend wound care into the home. With APIS®, we're putting a powerful, science-driven tool directly in the hands of physicians to treat a much broader range of patients immediately."

For full press release, click here.